Get the Stockscreener App
0.388
0.26%
-0.001
After Hours:
2.66
2.272
+585.57%
Gt Biopharma Inc stock is traded at $0.388, with a volume of 302.17K.
It is down -0.26% in the last 24 hours and down -6.39% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.389
Open:
$0.37
24h Volume:
302.17K
Relative Volume:
0.29
Market Cap:
$12.24M
Revenue:
-
Net Income/Loss:
$-45.68M
P/E Ratio:
-0.0265
EPS:
-14.6193
Net Cash Flow:
$-12.91M
1W Performance:
-4.13%
1M Performance:
-6.39%
6M Performance:
-47.10%
1Y Performance:
-83.63%
1-Day Range:
$0.37
$0.39
1-Week Range:
$0.3506
$0.409
52-Week Range:
$0.3506
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.82 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.85 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.70 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.81 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.21 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
GTBP Forecast, Price Target & Analyst Ratings | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
GT Biopharma enters agreement with University of Minnesota for phase 1 trial - Investing.com Australia
GT Biopharma enters agreement with University of Minnesota for phase 1 trial By Investing.com - Investing.com South Africa
GT Biopharma Advances GTB-5550 via University Trial Pact - TipRanks
GT Biopharma (NASDAQ: GTBP) backs $3.8M GTB-5550 cancer trial pact - Stock Titan
GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota - marketscreener.com
GTBP SEC FilingsGt Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VIX Spike: Will GT Biopharma Inc benefit from government policyTrade Risk Assessment & Stepwise Swing Trade Plans - baoquankhu1.vn
Analyst Calls: Will GT Biopharma Inc benefit from government policyWeekly Trend Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Recap Report: Can GT Biopharma Inc outperform under higher oil prices2026 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
If You Invested $1,000 in Gt Biopharma Inc (GTBP) - Stock Titan
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Purple Biotech Ltd (PPBT) - Stock Titan
GTBP Stock Chart | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
Published on: 2026-03-21 08:49:55 - baoquankhu1.vn
Panic Selling: Can GT Biopharma Inc outperform under higher oil prices2026 Rallies & Technical Entry and Exit Alerts - baoquankhu1.vn
GT Biopharma (GTBP) upgraded to buy: Here's what you should know - MSN
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
GT Biopharma (GTBP) Raised to Buy: Key Information You Need - Bitget
GT Biopharma (GTBP) forms 'hammer chart pattern': Time for bottom fishing? - MSN
GT Biopharma (GTBP) Develops 'Hammer Chart Pattern': Is It an Opportunity to Buy at the Bottom? - Bitget
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Should I buy GT Biopharma (GTBP) - Zacks Investment Research
GT Biopharma to Participate in the 38th Annual Roth Conference - Bitget
GT Biopharma CEO heads to 38th Roth conference for investor meetings - Stock Titan
GT Biopharma, Inc. Files Restated Q3 2025 10-Q/A Due to Greenshoe Rights Liability Accounting Error - Minichart
GT Biopharma, Inc. 2025 Q2 Amended Quarterly Report (10-Q/A): Restatement Due to Greenshoe Rights Liability, Financial Statements & SEC Compliance - Minichart
Will GT Biopharma Inc. (OXIA) stock beat value stocksWeekly Profit Summary & Technical Pattern Based Buy Signals - Naître et grandir
Stock Market Recap: Can GT Biopharma Inc outperform under higher oil pricesJuly 2025 Momentum & Consistent Return Investment Signals - baoquankhu1.vn
GT Biopharma (NASDAQ: GTBP) restates Q2 2025 and warns on going concern - Stock Titan
[10-Q/A] GT Biopharma, Inc. Amended Quarterly Earnings Report | GTBP SEC FilingForm 10-Q/A - Stock Titan
GTBP Earnings History & Surprises | EPS & Revenue Results | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans - Barchart
GTBPForm 8-KCurrent report - Revista ADVFN
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting - Investing.com UK
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting By Investing.com - Investing.com South Africa
GTBP: Net loss increased to $28.4M in 2025, with cash runway projected through Q4 2026 - TradingView
GT Biopharma 2025 10‑K: $0 Revenue, $(6.68) EPS, $28.35M net loss - TradingView
GT Biopharma (NASDAQ: GTBP) details cash strain, losses and $20M equity line - Stock Titan
GTBP: Net loss rose to $28.4M in 2025, with ongoing liquidity risks and urgent need for new capital - TradingView
Restatement of 2025 quarters at GT Biopharma (NASDAQ: GTBP) - Stock Titan
GT Biopharma Reports Full Year 2025 Financial Results - marketscreener.com
Cancer trial firm GT Biopharma says $9M cash funds work into late 2026 - Stock Titan
GT Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Should I Buy GTBP? GTBP 2026 AnalysisIntellectia AI™ - Intellectia AI
Can GT Biopharma Inc. outperform under higher oil pricesJuly 2025 Snapshot & Verified Swing Trading Watchlist - mfd.ru
Why GT Biopharma Inc. (OXIA) stock could be top winnerPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - The Manila Times
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):